Background. Elevated tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment is a known positive prognostic factor in colorectal cancer (CRC). We hypothesized that since cytotoxic T cells release cytolytic proteins such as perforin (PRF1) and pro-apoptotic granzymes (GZMA) to attack cancer cells, a cytolytic activity score (CYT) would be a useful tool to assess anticancer immunity.
(TILs) has been identified as a positive prognostic factor for CRC, with decreased tumor invasiveness, less nodal involvement, earlier-stage tumors, and improvement in survival. [6] [7] [8] [9] [10] High levels of CD8? (cytotoxic) TILs have also been noted to be good markers of response to neoadjuvant chemotherapy. 4 Thus, the current dogma is that cancer biology and patient outcomes are at least partly determined by immune cells within the tumor microenvironment. We hypothesized that it is not merely the existence of the immune cells, but rather their antitumoral cytolytic activity, that translate to patient outcomes.
The granzyme-perforin pathway is a primary method by which cytotoxic lymphocytes destroy cancer cells. 11 Perforin (PRF1) creates pores within the target cell membrane and mediates the entry of granzymes, which are tryptases that cleave caspases and induce apoptosis. 11, 12 Rooney et al. devised a quantitative measure of immune cytolytic activity based on transcript levels of granzyme A (GZMA) and PRF1, which are upregulated with cytotoxic T-cell activation and can be used to calculate a cytolytic activity score (CYT). 13 We hypothesized that tumors with a higher mutation load and a greater degree of intratumoral immunogenicity would be associated with a higher CYT, which in turn would result in improved patient survival.
MATERIALS AND METHODS

Patient Cohort and Genomic Data Processing
Both the clinical and genomic data were acquired from The Cancer Genome Atlas (TCGA) CRC cohort within the Genomic Data Common (GDC) data portal through the R/Bioconductor package 'TCGAbiolinks' in September 2017.
14 Samples without gene expression data were excluded. The data used included 456 tumor samples with 39 matched normal samples. Somatic mutation data of 417 tumor samples were also retrieved in the Mutation Annotation Format (MAF) aligned against hg19. 15, 16 Gene expression data were obtained in RSEM format from the GDC and converted to transcripts per million (TPM) by a given gene's estimated fraction of transcripts and multiplying by 10. 6 The immune CYT was defined as the geometric mean of GZMA and PRF1 expression values in TPM. The threshold of dichotomization of the CYT-high and low groups was determined by comparing differences in overall survival (OS) between the two groups at multiple candidate cut-off points within the range of CYT; the optimal cut-off point that gave the most significant results was chosen. The classification of high and low groups for immune-related genes was also determined by this running Cox proportional hazard model. 17 A CIBERSORT 18 deconvolution algorithm was used to estimate the fraction of 22 immune cell types in each tumor tissue to evaluate intratumor immune cell composition. These 22 cell fractions were calculated via an online calculator (https://cibersort.stanford.edu/).
Microsatellite instability (MSI) status: MSI-high (MSI-H) and microsatellite stable (MSS) for 291 CRC subjects were obtained from a genomic classifier including [ 200,000 microsatellite loci created by Hause et al. 19 The current study was deemed exempt from Institutional Review Board evaluation because all information within TCGA is publicly accessible and de-identified.
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Statistical Analysis
All statistical analyses were performed using R software (https://www.r-project.org/) and Bioconductor (https://ww w.bioconductor.org/). OS was defined as the time from date of diagnosis to death, while disease-free survival (DFS) was defined as the time from date of diagnosis to date of first recurrence, or date of death when no recurrence. The Kaplan-Meier method with log-rank test, and Cox proportional hazard models, were used to compare survival curves between groups. Hazard ratios (HRs) and 95% confidence intervals (CI) were provided when fitting the multivariate Cox models of CYT and other clinicopathological features. Through literature review, we identified six clinical factors (age, sex, lymphatic invasion, venous invasion, tumor location, stage) and two molecular factors (MSI and TIL status), which we used to perform a univariate analysis based on the Cox proportional hazard model for OS, with each clinical variable as covariates. Clinical variables that showed significance were then selected as covariates for multivariate analysis.
For continuous variables, the differences between the two groups were assessed using the Mann-Whitney test; for discrete variables, Chi square tests were used to evaluate the association between factors. Spearman correlation was used to describe the relationship between gene expressions and CYT. Unadjusted p-values were determined to be appropriate for this exploratory study. In all analyses, a two-sided p-value \ 0.05 was considered statistically significant.
RESULTS
Cytolytic Activity Score (CYT) was Low in Cancer Tissue and High in Microsatellite Unstable Colorectal Cancer with High Mutation Load
Of the 456-patient TCGA cohort, 221 patients (48.5%) were CYT-low and 235 patients (51.5%) were CYT-high. There was a normal distribution of cytolytic molecules throughout the cohort of CRC patients in TCGA (Supplementary Fig. S1 ).
Since CYT is a quantitative measurement of immune cytolytic activity, it is expected to be high in tissues where cytotoxic T cells infiltrate and are activated. Indeed, CRCs were found to have lower CYT than normal colon (p \ 0.0001) (Fig. 1a) . It was noted that MSI-H tumors were associated with high CYT compared with MSS (p \ 0.0001) (Fig. 1b) . We found that CYT-high tumors were associated with a higher mutational load than CYTlow tumors (p \ 0.0001) (Fig. 1c) . We further examined the association between CYT and significantly mutated genes (SMGs) in CRC. 24 Interestingly, of the SMGs, frequently mutated genes (APC and KRAS) showed a significantly negative association with CYT-high status, while several SMGs with less-frequent mutational events showed a significantly positive association with high CYT (Fig. 1d) .
CYT-High Associates with Tumor-Infiltrating Lymphocytes and Macrophages
Tumors with high CYT were significantly associated with high levels of TIL, including activated memory CD4?T cells, gamma-delta T cells, and M1 macrophages (p \ 0.0001). Interestingly, we did not note any elevation in CYT in CD8? T cells (p = 0.335). We also found that resting natural killer (NK) cells were significantly associated with CYT-high status (p \ 0.0001), and activated NK cells had greater association with CYT-low status (p = 0.0056) (Fig. 1e-i ). 
Clinicopathologic Features of CYT-High versus CYTLow Patients
There was no difference in mean age, sex, and lymphovascular invasion between CYT-high and CYT-low patients (Table 1 ). More CYT-high patients had right-sided CRC than left-sided CRC (p = 0.01). CYT-high patients also had early-stage (I and II) cancers compared with the CYT-low group (p = 0.005). Univariate analysis (Table 2) determined that male sex, lymphatic and vascular invasion, and stage IV disease adversely impacted survival, whereas CYT-high status was a significant positive prognostic factor. In subsequent multivariate Cox regression analysis (Table 2) , only female sex and CYT-high status remained as factors associating with improved survival independently after controlling for age, lymphovascular invasion, colonic location, MSI, and TIL positivity.
CYT-High Patients Have Improved Survival
We found that CYT-high patients have significantly improved median and 5-year OS and DFS compared with CYT-low patients (Fig. 2a, b) . Median OS for the CYThigh cohort was 101.4 months, compared with 66.7 months in the CYT-low cohort. Five-year OS was also significantly better in CYT-high patients compared with CYT-low patients (69.1% vs. 57.9%, p = 0.019). A significant difference in median DFS was also seen between CYT-high and CYT-low patients (72.5 vs. 40.5 months). Five-year DFS was 58.4% for CYT-high patients, compared with 40.8% in CYT-low patients (p = 0.016).
We especially noted an improvement in survival in the CYT-high patients who were also found to be TIL-positive, as determined by higher CD8? T-cell composition, than the mean value within the TCGA CRC cohort (Fig. 2c, d ). Median OS was not reached at 125 months in the CYThigh group, compared with 63.7 months in the CYT-low group, even when all included patients had TIL-positive tumors (p = 0.066). Similarly, median DFS in TIL-positive, CYT-high patients was also not reached in this time period, compared with 47.4 months in the CYT-low group (p = 0.027). Conversely, patients who were TIL-negative did not show significant improvement in OS and DFS compared with CYT-high patients (electronic supplementary Fig. S2 ).
Effect of CYT and its Association with Immune Checkpoint Molecules (ICMs) on Patient Survival
We found that high expression of several immune checkpoint molecules (ICMs), i.e. programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), lymphocyteactivation gene 3 (LAG3), T-cell immunoglobulin and mucin domain 3 (TIM3), and indoleamine 2,3-dioxygenase 1 (IDO1), directly associate with high CYT, with differences in survival based on their expression (Fig. 2e-k) . We found that patients with high CYT and low ICM expression had significantly superior survival compared with other patients in the cohort. (Fig. 2i) . 
CYT Correlates with Expression of ICMs
We found that high expression of the most common ICMs (PD-1, PD-L1, CTLA4, LAG3, TIM3, and IDO1) directly correlated with high CYT (Spearman correlation 0.70-0.81, p \ 0.0001) (Fig. 3a-f) . A similar correlation was seen between high CYT and high expression of FOXP3 (Spearman correlation 0.58, p \ 0.0001) (Fig. 3g) . This same trend was noted with the lesser-known checkpoint molecules IDO2, TIGIT, A2AR, and VISTA, as well as an inhibitory checkpoint index (described by Balli et al. 12 ) created to assess the expression of key checkpoint molecules across CRC patients, as well as Treg markers chemokine receptor (CCR) 4, CCR5, and interleukin-2 receptor antagonist (IL2RA; p \ 0.0001) ( Supplementary  Fig. S3 ).
DISCUSSION
The concept of immunoediting has become increasingly important in understanding the immune system's ability to control tumor growth and spread in a variety of cancer types. 25 Higher infiltration of lymphocytes and macrophages into the tumor microenvironment is known to associate with favorable outcomes in several cancers, including CRC. 25 We hypothesized that improvement in patient outcomes with TILs are related to increased anticancer cytolytic activity, which we are able to quantitate by CYT, rather than TIL numbers. CYT is associated with MSI-H tumors, mutational load, and TIL infiltration, but not with mutations in KRAS or APC, likely due to their lack of association with MSI or TIL. We also found that CYT-high patients demonstrated significant improvement in OS and DFS compared with CYT-low patients (especially in TIL-positive patients), an association not previously reported in CRC.
We found that MSI-H tumors were significantly associated with high CYT compared with MSS tumors. It is known that MSI-H CRC has 10-to 100-fold more somatic mutations than MSS, with prominent lymphocytic infiltrate into these tumors due to increased neoantigen load. 4, 5, 13, 26, 27 Since CYT measures intratumoral immune cytolytic activity, it makes sense to see high CYT associating with high TIL conditions such as MSI-H CRC. In several studies, patients with MSI-H tumors have also been found to have improved survival compared with their MSS counterparts. 1, 5 This may be attributed to the elevation in cytolytic activity within their cancer cells secondary to increased TIL infiltration.
We also found associations between certain immune cells and elevated CYT, likely due to their status as cytolytic effectors. CYT-high tumors have more infiltration of activated memory CD4? T cells, whereas they did not for resting memory CD4? T cells or naïve CD4? T cells. This is likely secondary to reactivation of these CD4? memory T cells by tumor antigens, resulting in stimulation of effector cytotoxic T cells and elevated CYT. 28, 29 Gamma-delta T cells are a subset of cytotoxic T cells that produce tumor necrosis factor (TNF)-a, resulting in cell-mediated lysis of tumor cells, and had more infiltration into CYT-high tumors within our analysis. 30 M1 macrophages were also identified as being Bold data indicates significant difference HR hazard ratio, CI confidence interval, MSI-H microsatellite instability-high, MSS microsatellite stable, TIL tumor-infiltrating lymphocyte associated with CYT-high tumors, likely due to their known role in inflammatory response and antitumor immunity via the release of proinflammatory cytokines such as TNFa. 31 Conversely, no increase in M2 macrophages was seen in CYT-high tumors, probably secondary to their function in tumor progression. 31 We also found an association between CYT-high tumors and resting NK cells, compared with activated NK cells. The reason for this is difficult to elucidate with CIBERSORT alone given that NK cells are known to be a highly diverse lymphocyte population with unique regulation and activation processes. 32 ICMs are an immune-inhibitory mechanism by which cancer cells may evade antitumor immune cells. 33 PD-1 expressed on T cells is initially bound by its ligand (PD-L1), resulting in negative regulation of T-cell antitumoral activity, deemed 'T-cell exhaustion'. 6, 33 Other ICMs include CTLA-4, which has been targeted by ipilimumab in the treatment of metastatic melanoma, LAG3, TIM3, and IDO1. [34] [35] [36] In our analyses, higher expression of the ICMs PD-1, PD-L1, CTLA4, LAG3, TIM3, and IDO1 were directly correlated with higher CYT. In their evaluation of CYT in pancreatic adenocarcinoma, Balli et al. found that CYT-high tumors were concurrently enriched with activated CD8?, PD-1-high T cells. 12 These findings indicate that elevation of cytotoxic TILs with higher CYT results in contemporaneous upregulation of ICMs that function as 'brakes'.
Higher levels of the Treg marker FOXP3 were also directly related to high CYT. Tregs are CD4? T cells that inhibit the function of tumor-specific T cells by expressing immunosuppressive cytokines such as interleukin (IL)-10 and transforming growth factor (TGF)-ß, as well as ICMs, and have been determined to be independent predictors of poorer survival when found in the tumor-immune microenvironment. [37] [38] [39] A positive correlation has also been noted between CD8? and FOXP3? cell counts, indicating that tumors utilize Treg to counteract elevated and its effect on patient survival. High, high expression of each gene; low, low expression of each gene. TIL tumor-infiltrating lymphocyte, CYT cytolytic activity score, PD-1 programmed death-1, PD-L1 programmed death-ligand 1, CTLA4 cytotoxic T-lymphocyteassociated protein 4, LAG3 lymphocyte-activation gene 3, TIM3 T-cell immunoglobulin and mucin domain 3, FOXP3 forkhead box P3, IDO1 indoleamine 2,3-dioxygenase 1, CRC colorectal cancer, TCGA The Cancer Genome Atlas, Treg regulatory T cell cytotoxic T cells. 40, 41 It has been reported that poorer prognosis of tumors with a high density of Treg is likely a result of an unfavorable ratio to cytotoxic T lymphocytes, rather than the number of Tregs alone. 41 We similarly identified poorer survival with higher expression of ICMs and Treg, which diminished the improvement in survival demonstrated in CYT-high patients.
The developments of immune checkpoint inhibitors have become increasingly popular in the treatment of a variety of cancer types. 6, 34, 42, 43 In their phase II trial examining anti-PD-1 blockade, Le et al. found a significantly improved objective response rate and survival in MSI-H CRC compared with MSS with associated TIL elevation. 44 The efficacy of these checkpoint inhibitors is likely correlated to their ability to obtain a cytolytic response, as denoted by CYT. Given CYT's correlation with ICM expression in this analysis, it is expected that CYT-high tumors may have a superior response to immune checkpoint inhibition. Thus, measurement of CYT could possibly be used as a predictive biomarker of the efficacy of immune checkpoint blockade, or of a tumor's possible responsiveness to immunotherapy. Interestingly, we found that CYT-high patients with high expression of ICM showed poorer survival. This may reflect the fact that these ICMs are also known as T-cell exhaustion markers, which may determine survival despite concurrent cytolytic activity. This allows us to speculate that this population may benefit the most from immune checkpoint inhibition. Some limitations in the present study included our inability to obtain precise information regarding patients' comorbid conditions and therapeutic interventions from TCGA. We also could not assess underlying molecular mechanisms, given our bioinformatics approach.
CONCLUSIONS
CYT-high CRC is associated with improved OS and DFS, likely due to enhanced anticancer immunity. This is especially true of tumors with increased mutation load and MSI that have increased cytolytic T cell and M1 macrophage burden. High CYT is also associated with high expression of ICMs and Tregs, likely due to concurrent elevation of cytolytic effectors. Thus, further studies to elucidate the role of CYT as a predictive biomarker of the efficacy of immune checkpoint blockade are warranted.
